Abstract:Abstract Therapeutic blockade of co-inhibitory immune receptors PD-1 and CTLA-4 has revolutionized oncology, but treatments are limited by immune-related adverse events (IRAEs). IRAE Colitis (irColitis) is the most common, severe IRAE affecting up to 25% of patients on dual PD-1 and CTLA-4 inhibition. Here, we present a systems biology approach to define the cell populations and transcriptional programs driving irColitis. We collected paired colon mucosal biopsy and blood specimens from 13 patients with irColitis, 8 healthy individuals, and 8 controls on immune checkpoint inhibitors (ICIs), and analyzed them with single-cell/nuclei RNA sequencing with paired TCR and BCR sequencing, multispectral fluorescence microscopy, and secreted factor analysis (Luminex). We profiled 299,407 cells from tissue and blood and identified 105 cell subsets that revealed significant tissue remodeling in active disease. Colon mucosal immune populations were dominated by tissue-resident memory (T RM ) ITGAE -expressing CD8 T cells representing a phenotypic spectrum defined by gene programs associated with T cell activation, cytotoxicity, cycling, and exhaustion. CD8 T RM and effector CD4 T cells upregulated type 17 immune programs ( IL17A, IL26 ) and Tfh-like programs ( CXCL13, PDCD1 ). We also identified for the first time an increased abundance of two KLRG1 and ITGB2 -expressing CD8 T cell populations with circulatory cell markers, including a GZMK T RM -like population and a CX3CR1 population that is predicted to be intravascular. These two populations were more abundant in irColitis patients treated with dual PD-1/CTLA-4 inhibition than those receiving anti-PD-1 monotherapy. They also had significant TCR sharing with PBMCs, suggesting a circulatory origin. In irColitis we observed significant epithelial turnover marked by fewer LGR5 -expressing stem cells, more transit amplifying cells, and upregulation of apoptotic and DNA-sensing programs such as the cGAS-STING pathway. Mature epithelial cells with top crypt genes upregulated interferon-stimulated pathways, CD274 (PD-L1), anti-microbial genes, and MHC-class II genes, and downregulated aquaporin and solute-carrier gene families, likely contributing to epithelial cell damage and absorptive dysfunction. Mesenchymal remodeling was defined by increased endothelial cells, both in irColitis patients and specifically in patients on dual PD-1/CTLA-4 blockade. Cell-cell communication analysis identified putative receptor-ligand pairs that recruit CD8 T cells from blood to inflamed endothelium and positive feedback loops such as the CXCR3 chemokine system that retain cells in tissue. This study highlights the cellular and molecular drivers underlying irColitis and provides new insights into the role of CTLA-4 and PD-1 signaling in maintaining CD8 T RM homeostasis, regulating CD8 T recruitment from blood, and promoting epithelial-immune crosstalk critical to gastrointestinal immune tolerance and intestinal barrier function.

Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis

Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors

Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

P001 Immune Checkpoint Inhibitor-Induced Colitis is Mediated by Polyfunctional Lymphocytes and is Dependent on the IL23/IFNg Axis

Dysregulation of CD4 + and CD8 + resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis

P38 Immune Checkpoint Inhibitor-Induced Colitis is Mediated by CXCR6+ Polyfunctional Lymphocytes and Dependent on IL23/IFNg Axis

Microbiota-dependent activation of CD4 + T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors

Checkpoint Inhibitor-Induced Colitis: An Update

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies

CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner

Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

P122 Digital spatial profiling reveals the predictive characteristics in patients with immune checkpoint inhibitor-induced colitis

In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Immune Checkpoint Inhibitor-Induced Colitis with Endoscopic Evaluation in Chinese Cancer Patients: a Single-Centre Retrospective Study

Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis